Andy Billinton PhD appointed as Chief Scientific Officer
Expansion into larger facilities at the Babraham Research Campus
Cambridge, 23rd June 2022: Transine Therapeutics today announced the appointment of Andy Billinton as Chief Scientific Officer as it triples its facility footprint at The Babraham Research Campus.
A Charnwood Campus Cluster event, part of a series of events to support the growth and success of the life science organisations clustered around Charnwood Campus Science, Innovation and Technology Park
Scorching temperatures, sizzling burgers and great company awaited members of the Norwich Research Park community who joined Anglia Innovation Partnership LLP (AIP) at their community summer barbecue sponsored by Chadwicks and Fortus.
The event was held on the grass and terrace area just outside the Centrum building attended by over 200 guests, from businesses and park partner organisations, who joined in the fun with networking, games and great food from the Genuine Dining Company.
Expansion of European business development team supports next phase of growth for Metrion’s ion channel drug discovery services
KISS Communications announced today its merger with digital agency Isle Interactive, adding
significant resources and strengthening its position as a leading creative agency.
The merger gives the award-winning agency the foundation to achieve its ambitious growth plans and
broaden and strengthen its offer across marketing and brand strategy, campaign development, inmarket
activation and digital delivery – with creativity at its heart.
Prof. Claire Thompson, multi award-winning CEO of Agility Life Sciences, has been recognised as one of the Top 10 Leaders in the field of small molecules on the 2022 Medicine Maker Power List.
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH A TOP 5 GLOBAL PHARMACEUTICAL COMPANY
Development of stable injectable high concentration formulations for its proprietary products
Cambridge, UK, 16 June 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a top five global pharmaceutical company.
Leading contract research organisation (CRO) Cellomatics Biosciences has moved into new purpose-built premises in Nottingham in the wake of rising demand for its bespoke preclinical and early drug discovery phase laboratory services.